{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nsaids-prescribing-issues/background-information/mode-of-action/","result":{"pageContext":{"chapter":{"id":"d742f98e-351a-50ba-bc7a-d0ecc0e7689d","slug":"mode-of-action","fullItemName":"Mode of action","depth":2,"htmlHeader":"<!-- begin field 334bd46b-71ae-4366-b530-e4c2dfb70098 --><h2>Mode of action</h2><!-- end field 334bd46b-71ae-4366-b530-e4c2dfb70098 -->","summary":"","htmlStringContent":"<!-- begin item 6d223594-c5fc-431e-8e60-01ea7c3cda5a --><!-- begin field 8f3746d4-de68-4f53-9512-173adeede58b --><ul><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) act peripherally and centrally, however the peripheral action predominates.</li><li>NSAIDs inhibit prostaglandin synthesis, which normally potentiates the pain caused by other inflammatory mediators (such as histamine and bradykinin).</li><li>NSAIDs work by reversibly inhibiting cyclo-oxygenase (COX) enzymes — the two main types of COX enzyme are COX-1 and COX-2, which have different physiological functions.<ul><li>COX-1 produces prostaglandins that help to maintain gastric mucosal integrity and platelet-initiated blood clotting.<ul><li>COX-1 is present in most tissues.</li><li>Inhibition of COX-1 is thought to be responsible for gastrointestinal toxicity.</li></ul></li><li>COX-2 produces prostaglandins that mediate pain and inflammation.<ul><li>COX-2 is usually undetected in tissues and is produced in response to inflammatory cytokines.</li><li>Inhibition of COX-2 is thought to be responsible for the anti-inflammatory action of NSAIDs.</li></ul></li></ul></li><li>NSAIDs vary in how selective they are for COX-1 and COX-2 pathways.<ul><li>The degree of selectivity for COX-1 relative to COX-2 can be used to classify NSAIDs.</li><li>There is no absolute selectivity for one or other COX enzyme — even highly selective COX-2 inhibitors will also inhibit COX-1 at high enough concentrations.</li></ul></li><li>Aspirin is not included in this CKS topic, although it is technically a standard NSAID (it inhibits COX enzymes). Aspirin is now mainly used for antithrombotic effects, which is due to permanent inhibition of the COX-1 pathway in platelets.<ul><li>Standard NSAIDs may also inhibit the COX-1 pathway in platelets, but the inhibition is too short-lived for them to have a useful antithrombotic effect.</li><li>For more information on low-dose aspirin, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">Neal, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">Schmidt, 2016</a>]</p><!-- end field 8f3746d4-de68-4f53-9512-173adeede58b --><!-- end item 6d223594-c5fc-431e-8e60-01ea7c3cda5a -->","topic":{"id":"ceac2e33-6fd9-5bdf-a103-bdeff3e6efe7","topicId":"5e29889f-d8f4-4f4e-9bce-78c262cd5e62","topicName":"NSAIDs - prescribing issues","slug":"nsaids-prescribing-issues","lastRevised":"Last revised in April 2020","chapters":[{"id":"81e21dc7-3fa3-5a27-a799-d7e553aa1b01","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e5927ea9-133a-5f9b-a357-a61c0992b6c6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f8ed8fe1-df7d-5125-937f-2d1e3501233c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f6920c2a-03f6-5506-aec1-3fdde89dd2f7","slug":"changes","fullItemName":"Changes"},{"id":"7e3ebe71-e455-5372-ae22-416ce6a0b71a","slug":"update","fullItemName":"Update"}]},{"id":"acb8e014-609e-5dc6-9f65-30c1458821c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"93d7bec8-79d3-5e43-b717-afe25c73d3ca","slug":"goals","fullItemName":"Goals"},{"id":"80a6271f-7ea5-5a98-902b-a008dc09f1ee","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6782e03f-1ef7-5af4-86c0-eb675a202116","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fcacc99e-0dfb-5679-b56f-f8205eba1edc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"15a07f25-5af2-57a1-a7ac-048177f2fb99","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"39c204ac-0dfe-5334-ba6a-72f81053bd3d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9ce106c0-0dc6-5564-9353-be22c8fc1ed5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0cc396a7-37bb-55ac-a9b6-83b76805f342","slug":"definition","fullItemName":"Definition"},{"id":"d742f98e-351a-50ba-bc7a-d0ecc0e7689d","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"93f69297-618f-59f0-b4d4-f6e50bdf5467","slug":"classification","fullItemName":"Classification"}]},{"id":"6537c6fb-b310-5291-98df-d01a4e961e7e","fullItemName":"Management","slug":"management","subChapters":[{"id":"f7cf8186-98aa-5332-bbd7-7ac7f7c5748e","slug":"nsaids-prescribing-issues","fullItemName":"Scenario: NSAIDs  prescribing issues"}]},{"id":"1e3b7407-6a49-5511-bff4-c0f0e8e7b22e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"56eccf0e-4660-56df-8972-3fc937ad78b7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"80126798-6f53-5ceb-b2d7-d2c5adf206da","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0e838f63-dbcc-5df4-ba98-67f8c94448ed","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"179593fd-6f34-5834-a706-a5b7abb725a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b21e3781-fcad-52bd-b0b3-0b7f267e817d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ece91260-71c4-51d6-bc77-400de18b4802","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dedb4c68-d2e7-53bb-81ef-03a9600c383d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9ce106c0-0dc6-5564-9353-be22c8fc1ed5","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}